CN1066628C - Medicine for chronic hepatitis B and its preparation - Google Patents
Medicine for chronic hepatitis B and its preparation Download PDFInfo
- Publication number
- CN1066628C CN1066628C CN97107958A CN97107958A CN1066628C CN 1066628 C CN1066628 C CN 1066628C CN 97107958 A CN97107958 A CN 97107958A CN 97107958 A CN97107958 A CN 97107958A CN 1066628 C CN1066628 C CN 1066628C
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- rhizoma
- medicament
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicament for curing chronic hepatitis and a preparation method. The medicament for curing chronic hepatitis is prepared from traditional Chinese medicaments used as raw materials, wherein the components of the raw materials mainly comprise 18 tastes of medicaments of oldenlandia, glabrous greenbrier rhizome, aweto, giant knotweed rhizome, oriental wormwood, milk vetch, red sage roots, Chinese taxillus herb, largehead atractylodes rhizome, rhubarb, curcuma roots and other traditional Chinese medicaments, and a triple-clearing capsule for curing hepatitis is prepared. The medicament for curing chronic hepatitis starts form the purposes of clearing viruses and enhancing immunity to improve the liver function and to reduce transaminase according to a cure principle of 'eliminating fever, dissipating dampness, supporting healthy energy and activating blood circulation to dissipate blood stasis'; the prescription is scientific, the Yin transfer of a 'triple Yang' index of HBV is promoted, and the curative effect on the chronic hepatitis is enhanced; when the medicament is applied, the effect-taking rate reaches 45.25%, the effective rate reaches 43.6%, and the utility model etotal effective rate reaches 88.7%; and the curative effect of the medicament for curing chronic hepatitis is higher than that of a national-level new medicament of 'a Fugankang granule for curing hepatitis' and the existing medicaments for curing hepatitis at home.
Description
The present invention relates to a kind of medicine for the treatment of chronic viral hepatitis B, is the Chinese patent medicine of feedstock production with Chinese medicine specifically, the invention still further relates to the preparation method of this medicine.
Hepatitis B has become pandemic immune disease, because the western medicine effect is not good enough, so the Chinese medicine hepatitis B has become the difficult point and the focus of world's hepatopathy research.According to the retrieval of Hunan Province's Chinese medicine technical information center, the scientific and technical literature relevant with hepatitis has 683 pieces, and the new Chinese patent medicine of treatment chronic viral hepatitis B has the Chaoyang ball of Chaoyang District Beijing.Other have the AOTAILE electuary, set upright Liver-recovering capsule, hepatitis spirit, Ke Boli, the clean sheet of liver poison, Radix Astragali oral liquid etc.The YIGANNING CHONGJI treatment chronic viral hepatitis B experiment of Hunan Inst of Traditional Chinese Medicine development obtains 1992 annual State Administration of Traditional Chinese Medicine scientific and technological progress second prizes with clinical research.Nineteen ninety-five " Nanjing University of Traditional Chinese Medicine's journal " has been delivered the research of the clean sheet treatment of the liver poison chronic viral hepatitis B of golden wonderful article.The manufacture method that has the sharp liver of CN1032295 to swell of " Chinese medicine patent complete works " record, CN1075422 AOTAILE electuary, CN1083712A medicine of preventing and treating hepatitis B, CN1077379 instant particles for treating hepatitis B, patent documentations such as CN1076626 Medicine taken after being mixed with boiling water for liver trouble.The Chinese medicine hepatitis B makes progress.Though the treatment hepatitis B medicine is many, curative effect is not ideal, does not make a breakthrough as yet.Still there is not the radical cure medicine of generally acknowledging so far both at home and abroad.Using Chinese medicine and differential diagnosis in tcm opinion and control, is 50～90% to reducing the SGP total effective rate, normalization rate 41～87%, knock-on rate 23～33% after the drug withdrawal.For the HBSAg negative conversion rate, Chinese medicine compound is 10～75.9%, and it is 12～87% that dialectical opinion is controlled, HBeAg negative conversion rate 20～90% anti-HBc negative conversion rates 14.3%.
The object of the present invention is to provide a kind of good effect, have no side effect, have the chronic hepatitis B therapeutic agent of removing virus, human body immunity improving function, suppressing humoral immunization.
Another object of the present invention provides the preparation method of this treating hepatitis B agent.
Solution of the present invention is based on motherland's medical science to pathogenetic understanding of chronic viral hepatitis B and Therapeutic Principle.The chronic viral hepatitis B pathogenesis is " damp and hot surplus heresy is residual not to the greatest extent, stagnation of liver-QI with deficiency of the spleen, asthenia of qi and blood ".It is strongly fragrant that the poison heresy does not show as the damp and hot stasis of blood to the greatest extent, and healthy energy void shows as insufficiency of the spleen Liver and kidney void.So from a large amount of Chinese medicines, filter out the Chinese medicine of clearing away heat and eliminating dampness, strengthening the body resistance, blood circulation promoting and blood stasis dispelling, tonifying speen and tonifying kidney, by the theory of Chinese medical science prescription, make its performance remove hepatitis b virus marker, improve cellular immune function, suppress humoral immunization, the synergism of multi-level performance medicine, improve clinical symptoms and liver function, bring into play comparatively ideal effect.
Medicine of the present invention is made (consumption is a weight portion) by following component:
8～25 parts of 8～20 parts of Radixs Astragali of 8～20 parts of Rhizoma Smilacis Glabraes of Herba Hedyotidis Diffusae
8～15 parts of Rhizoma Polygoni Cuspidati 6～15 valencys of 8～20 portions of Herba Artemisiae Scopariaes of Radix Salviae Miltiorrhizae
6～15 parts of 6～15 parts of Radix Codonopsis of 6～15 portions of Semen Coiciss of Fructus Lycii
6～15 parts of 6～15 portions of Radix Curcumaes of 6～15 parts of Rhizoma Atractylodis Macrocephalaes of the Radix Paeoniae Alba
5～15 parts of 8～15 parts of Radix Bupleuri of 8～15 parts of Herba Taxillis of the Radix Polygoni Multiflori
3～8 parts in 4～10 portions of Radix Glycyrrhizaes of 0.5～3 part of Radix Et Rhizoma Rhei of Cordyceps
The preferred weight proportioning of medicine of the present invention is:
12 parts of 16 parts of Radixs Astragali of 10 parts of Rhizoma Smilacis Glabraes of Herba Hedyotidis Diffusae
10 parts of 10 parts of Rhizoma Polygoni Cuspidati of 15 portions of Herba Artemisiae Scopariaes of Radix Salviae Miltiorrhizae
10 parts of 12 parts of Radix Codonopsis of 10 portions of Semen Coiciss of Fructus Lycii
10 parts of 10 portions of Radix Curcumaes of 10 parts of Rhizoma Atractylodis Macrocephalaes of the Radix Paeoniae Alba
12 parts of 10 parts of Radix Bupleuri of 10 parts of Herba Taxillis of the Radix Polygoni Multiflori
6 parts in 8 portions of Radix Glycyrrhizaes of 2 parts of Radix Et Rhizoma Rhei of Cordyceps
It is to take by weighing raw material in proportion that above-mentioned each component is made medicine production method of the present invention:
1, fetches earth earlier and pulverized sieve No. 5 after Poria, the Cordyceps clean dry, need not decoct;
2, Radix Curcumae, the Radix Paeoniae Alba being cleaned the oven dry back pulverizes;
3, decoction pieces is concocted in Rhizoma Polygoni Cuspidati, the Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei processing;
4, Herba Hedyotidis Diffusae, Semen Coicis, Herba Artemisiae Scopariae, Fructus Lycii, the Radix Astragali, Radix Codonopsis, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, Herba Taxilli star, Radix Bupleuri are removed impurity, clean; Add Rhizoma Polygoni Cuspidati, the Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, soaked 15～20 hours.Decocted (slow fire is little after boiling boils) for the first time 2.5 hours, twice decoction of surplusing respectively 1.5 hours;
5, boil liquid mixing placement with three times and spend the night, reconcentration is handled and is reached 1.1 proportion; System extractum is prevented the bottom of a pan mass with 0.5 pound of low temperature control air pressure, reaches hot 1.25 proportions of surveying and gets final product;
6, with thick paste and ready-formed medical material fine powder mixing, dry porphyrize is crossed sieve No. 5, filling capsule then, every 0.3g, 60 of every capsules, name " three clear hepatitis B capsules " temporarily.
Drug quality control of the present invention is fine powder moisture＜9%, and system cream and powder process must not have smell of scorching and roasting burning.
The clinical use result of 1991～nineteen ninety-five of medicine of the present invention shows that following advantage is arranged:
1, to select conventional plant amedica for use be raw material in the present invention, and each component meets the pharmaceutical control law regulation, and nontoxic to human body, drug safety is reliable.
2, the medicine source is extensive, easily adopts to be easy to get; Production technology is simple, taking convenience;
3, good effect, total effective rate reaches 88%, is higher than the curative effect (negative conversion rate of HBsAg, HBeAg is 13.6%, 49.2%) of national new drug " FUGANKANG agent " treatment chronic viral hepatitis B.
For showing the therapeutic effect of medicine of the present invention to chronic viral hepatitis B; the present invention is routine clinical observation through 124 examples; and select medical history, the state of an illness, age, patient's 32 examples that sex is suitable with the ALT value to compare group; diagnostic criteria by " viral hepatitis is prevented and treated scheme " of nineteen ninety Shanghai meeting revision; hepatitis history surpasses half a year, and a sharp above positive sign that has present situation HBV to infect.In 156 examples, maximum 65 years old age, minimal ages 4 years old, the longest course of disease 108 months, the shortest 6 months.Test group: every day, oral medicine of the present invention was 3 times, and each 5, warm water delivery service was taken 3 months continuously.Matched group: " hepatitis B strengthening capsule " that Changchun, oral Jilin every day produces 3 times, each 4, took continuously 3 months.
Curative effect determinate standard is with reference to the evaluating drug effect standard in " the clinical drug research guideline " of Ministry of Public Health formulation in 1988.Produce effects: symptom, sign disappear, and liver function is normal, and the hbv replication index all disappears.Effectively: symptom and liver function are all improved or the hbv replication index has the person of turning out cloudy more than.Observational technique adopts liver function observation index and immunology enzyme process hepatitis B " two double " index.Case is the every index of check before test and after the treatment all, clinical test results such as table 1.
Table 1 result of the test total effective rate relatively
| The example number | Produce effects (%) | Effectively (%) | Invalid (%) | Total effective rate % | |
| Test group | 124 | 56(45.2) | 54(43.6) | 14(11.3) | 88.7 |
| Matched group | 32 | 0 | 5(15.6) | 27(83.4) | 15.6 |
x
2=70.12 p＜0.005
Symptom contrast before and after table 2 treatment
" two double " index contrast before and after table 3 treatment
Test statistics shows that 3 index negative conversion rates: medicine of the present invention is respectively, HBsAg48.4%, and HBeAg89.5%, HBcAb54.6% is apparently higher than a domestic blood serum designated object negative conversion rate average level (35.53%, 58.71%) together.Take medicine of the present invention, obvious effective rate 45.2%, effective percentage 43.6%, total effective rate are 88.7%.Test group obviously is better than matched group.
Project of the present invention was listed the great scientific research plan of Hunan Province Department of Public Health " eight or five " in 1991 in, research through 5 years, on February 5th, 1996 in Changsha by provincial technical appraisement, Hunan Inst of Traditional Chinese Medicine traditional Chinese medical science researcher Ou Yangqi, hepatopathy researcher Zhang Bizi, the hepatopathy professor Liu Weishi of Hunan College of Traditional Chinese Medicine, Chen Ningsheng, the professor of Annex II institute of Hunan Medical University professor expert such as first lion that revives thinks: " this research selected topic meets clinical needs; prescription meets theory of Chinese medical science; data are more accurate, is reaching advanced international level aspect clinical efficacy in the recent period ".
Embodiment takes by weighing raw material by following proportioning:
12 kilograms of 15 kilograms of Radixs Astragali of 10 kilograms of Rhizoma Smilacis Glabraes of Herba Hedyotidis Diffusae
10 kilograms of 10 kilograms of Rhizoma Polygoni Cuspidati of 16 kilograms of Herba Artemisiae Scopariaes of Radix Salviae Miltiorrhizae
10 kilograms of 12 kilograms of Radix Codonopsis of 10 kilograms of Semen Coiciss of Fructus Lycii
10 kilograms of 10 kilograms of Radix Curcumaes of 10 kilograms of Rhizoma Atractylodis Macrocephalaes of the Radix Paeoniae Alba
12 kilograms of 10 kilograms of Radix Bupleuri of 10 kilograms of Herba Taxillis of the Radix Polygoni Multiflori
6 kilograms in 8 kilograms of Radix Glycyrrhizaes of 2 kilograms of Radix Et Rhizoma Rhei of Cordyceps
Production method is as follows: take by weighing raw material in proportion
1, fetches earth earlier and pulverized sieve No. 5 after Poria, the Cordyceps clean dry, need not decoct;
2, Radix Curcumae, the Radix Paeoniae Alba being cleaned the oven dry back pulverizes;
3, decoction pieces is concocted in Rhizoma Polygoni Cuspidati, the Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei processing;
4, Herba Hedyotidis Diffusae, Semen Coicis, Herba Artemisiae Scopariae, Fructus Lycii, the Radix Astragali, Radix Codonopsis, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae, Herba Taxilli star, Radix Bupleuri are removed impurity, clean; Add Rhizoma Polygoni Cuspidati, the Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, soaked 15～20 hours.Decocted (slow fire is little after boiling boils) for the first time 2.5 hours, twice decoction of surplusing respectively 1.5 hours;
5, boil liquid mixing placement with three times and spend the night, reconcentration is handled and is reached 1.1 proportion; System extractum is prevented the bottom of a pan mass with 0.5 pound of low temperature control air pressure, reaches hot 1.25 proportions of surveying and gets final product;
6, with thick paste and ready-formed medical material fine powder mixing, dry porphyrize is crossed sieve No. 5, filling capsule then, every 0.3g, 60 of every capsules.
Claims (4)
1, a kind of medicine for the treatment of chronic viral hepatitis B is characterized in that it is the medicament of being made by the following weight proportion raw material:
Herba Hedyotidis Diffusae 8-20 part Rhizoma Smilacis Glabrae 8-20 part Radix Astragali 8-25 part Radix Salviae Miltiorrhizae 8-20 part
Herba Artemisiae Scopariae 8-15 part Rhizoma Polygoni Cuspidati 6-15 part Fructus Lycii 6-15 part Semen Coicis 6-15 part
Radix Codonopsis 6-15 part Radix Paeoniae Alba 6-15 part Rhizoma Atractylodis Macrocephalae 6-15 part Radix Curcumae 6-15 part
Radix Polygoni Multiflori 8-15 part Herba Taxilli 8-15 part Radix Bupleuri 5-15 part Cordyceps 0.5-3 part
Radix Et Rhizoma Rhei 4-10 part Radix Glycyrrhizae 3-8 part
2, the medicine of treatment chronic viral hepatitis B according to claim 1, wherein the weight proportion of each raw material is:
15 parts of 12 parts of Radix Salviae Miltiorrhizaes of 15 parts of Radixs Astragali of 10 parts of Rhizoma Smilacis Glabraes of Herba Hedyotidis Diffusae
12 parts of 10 portions of Semen Coiciss of 10 portions of Fructus Lyciis of 10 parts of Rhizoma Polygoni Cuspidati of Herba Artemisiae Scopariae
10 parts of 10 portions of Radix Curcumaes of 10 parts of Rhizoma Atractylodis Macrocephalaes of 10 portions of Radix Paeoniae Albas of Radix Codonopsis
2 parts of 12 parts of Cordyceps of 10 parts of Radix Bupleuri of 10 parts of Herba Taxillis of the Radix Polygoni Multiflori
6 parts in 8 portions of Radix Glycyrrhizaes of Radix Et Rhizoma Rhei
3, medicine according to claim 1 and 2 is characterized in that said medicament is a capsule.
4, the preparation method of the medicine of the described treatment chronic viral hepatitis B of claim 3 is characterized in that taking by weighing raw material in described ratio, and Rhizoma Smilacis Glabrae, Cordyceps drying and crushing are crossed sieve No. 5; Radix Curcumae, the Radix Paeoniae Alba are cleaned the pulverizing of oven dry back to be soaked 15-20 hour together with the Rhizoma Polygoni Cuspidati of handling routinely, the Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Radix Et Rhizoma Rhei, Herba Hedyotidis Diffusae, Semen Coicis, Herba Artemisiae Scopariae, Fructus Lycii, the Radix Astragali, Radix Codonopsis, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae, Herba Taxilli, Radix Bupleuri, decocted 2.5 hours for the first time twice decoction of surplusing respectively 1.5 hours; The mixing of three liquid is spent the night, and concentration makes extractum; Decocting back system thick paste proportion is 1.25, with Rhizoma Smilacis Glabrae and full dose Cordyceps dry powder and extractum mixing, do the bath porphyrize cross sieve for No. 5 after, medicated powder is inserted in the capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97107958A CN1066628C (en) | 1996-02-15 | 1997-02-04 | Medicine for chronic hepatitis B and its preparation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96118054.4 | 1996-02-15 | ||
| CN96118054 | 1996-02-15 | ||
| CN97107958A CN1066628C (en) | 1996-02-15 | 1997-02-04 | Medicine for chronic hepatitis B and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1176123A CN1176123A (en) | 1998-03-18 |
| CN1066628C true CN1066628C (en) | 2001-06-06 |
Family
ID=25744033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97107958A Expired - Fee Related CN1066628C (en) | 1996-02-15 | 1997-02-04 | Medicine for chronic hepatitis B and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1066628C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1070378C (en) * | 1998-11-24 | 2001-09-05 | 雷玉宏 | Medicine for curing hepatitis B |
| CN1086129C (en) * | 1999-02-11 | 2002-06-12 | 唐本善 | Hepatitis restoration pill |
| CN1331466C (en) * | 2004-02-03 | 2007-08-15 | 上海和黄药业有限公司 | Medicine preparation for treating liver and gallbladder disease and its preparing process |
| CN100460010C (en) * | 2005-05-29 | 2009-02-11 | 王福山 | Chinese medicine composition for treating hepatitis B and viral hepatitis |
| CN101385842B (en) * | 2008-10-14 | 2010-12-29 | 王林兴 | Medicine for treating chronic hepatitis b and preparation method thereof |
| CN104784628A (en) * | 2015-03-18 | 2015-07-22 | 周珍光 | Traditional Chinese medicine composition for treating hepatitis B |
| CN107343948A (en) * | 2017-08-04 | 2017-11-14 | 成都市飞龙水处理技术研究所 | It is a kind of effectively to treat pill medicine of hepatitis B and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1083712A (en) * | 1993-04-11 | 1994-03-16 | 孟福厚 | A kind of medicine of preventing and treating hepatitis B |
| CN1109339A (en) * | 1994-03-31 | 1995-10-04 | 韩瑞星 | Powder for curing hepatitis B |
-
1997
- 1997-02-04 CN CN97107958A patent/CN1066628C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1083712A (en) * | 1993-04-11 | 1994-03-16 | 孟福厚 | A kind of medicine of preventing and treating hepatitis B |
| CN1109339A (en) * | 1994-03-31 | 1995-10-04 | 韩瑞星 | Powder for curing hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1176123A (en) | 1998-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1044974C (en) | Anti- hepatitis B preparation | |
| CN1162171C (en) | Gynopathy treating traditional Chinese medicine | |
| CN102755594A (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN1562160A (en) | Composite medicine for treating hepatitis B complication | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1475229A (en) | Antifatigue compound Chinese medicine prescription and its preparation method | |
| CN112891399A (en) | Traditional Chinese medicine composition and application and preparation method thereof | |
| CN101361946B (en) | Traditional Chinese medicine combination for treating hepatitis B | |
| CN1066628C (en) | Medicine for chronic hepatitis B and its preparation | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN100366269C (en) | Chinese medicine for treating AIDS | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN100534506C (en) | Chinese medicinal mixture for treating viral hepatitis | |
| CN105687579A (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN101695562B (en) | Chinese medicinal composition for treating viral hepatitis and preparation method thereof | |
| CN1557396A (en) | Chinese medicinal composition for treating hepatitis B | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN104147526A (en) | Traditional Chinese medicine particles for treating icteric hepatitis and preparation method thereof | |
| CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
| CN1101687C (en) | Liver-invigorating detoxication pill for treating hepatitis B | |
| CN1062463C (en) | Oral liquid | |
| CN104958662A (en) | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof | |
| CN1352966A (en) | Medicine for treating tracheitis and asthma | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN101229291B (en) | Chinese traditional medicine composition for treating virus hepatitis by immunoregulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010606 Termination date: 20130204 |